市场调查报告书
商品编码
1423674
2030 年服务实验室市场预测:按服务类型、应用和地区分類的全球分析Service Laboratory Market Forecasts to 2030 - Global Analysis By Service Type, By Application and By Geography |
根据 Stratistics MRC 的数据,全球服务实验室市场在预测期内将以 7.2% 的复合年增长率成长。
服务实验室涉及使用专用设备来监测医疗环境中电离辐射水平的测量和检测。这些设备透过追踪辐射暴露、评估 X 光、 电脑断层扫描和放射治疗等治疗期间的剂量以及保护患者和医护人员免受潜在的辐射过度暴露来帮助确保安全。我会确保安全。
根据疾病管制中心的数据,每年进行 140 亿次实验室检测。据估计,70% 的医疗决定是基于实验室测试结果。
诊断测试需求增加
随着人们对预防性医疗保健和疾病早期检测的日益关注,对准确和先进的诊断测试的需求日益增长。人口老化、慢性病增加、诊断工具技术进步等因素导致需求激增。因此,服务实验室透过增加对各种诊断测试的需求并满足医疗保健及相关行业对准确、及时和全面的诊断服务日益增长的需求来推动市场成长。
营运和资本成本高
它们需要最尖端科技、专业设备、熟练的人员,并严格遵守监管标准,导致营运成本高昂。此外,建立和维护最先进的实验室的初始投资也会增加您的资本成本。这些高昂的营运和资本成本给进入市场的中小企业带来了挑战,限制了它们的竞争力和创新投资能力。
个性化医疗的兴起
个人化医疗依赖于基于个人基因组成、生活方式和特定健康特征的精确诊断测试和客製化治疗。这一趋势刺激了对基因检测、生物标记分析和分子诊断等先进检测服务的需求,这些服务需要专门的实验室。个人化医疗服务实验室可以提供全面的检测服务,支援医疗保健提供者提供更有效、更有针对性的治疗,从而促进个人化医疗的发展,扩大服务实验室市场的机会。
不断的技术进步
快速的技术发展可能会使现有设备和方法过时,需要频繁升级和投资新技术。这种不断适应和创新的需求给实验室带来了保持竞争力的财务压力。此外,快速的变更可能会在更新的系统和旧有系统系统之间造成差距,影响检查程序的标准化和一致性,并迫使服务供应商采用新技术和服务。在确保连续性和可靠性之间保持平衡是一个潜在的挑战。
COVID-19 的疫情对服务实验室市场产生了重大影响,并导致诊断测试服务的需求增加。世界各地的实验室设施面临检测病毒的测试要求激增,导致业务挑战、供应链中断和劳动力限制。此外,疫情加速了研究和开发活动,并凸显了服务实验室在疾病诊断、治疗开发和公共卫生应对策略中的重要性。
预计常规测试部分在预测期内将是最大的
预计常规测试行业在预测期内将增长最大,这主要是由于其在各个行业和日常流程中的广泛应用。製药、食品和饮料和饮料以及製造业等行业都严重依赖常规测试来确保品质和遵守法规。因此,对常规和标准化测试程序的持续需求使得常规测试部分在预测期内成为广泛测试服务市场的主导和最大贡献者。
预计临床测试领域在预测期内复合年增长率最高
由于医疗保健支出的增加、预防医学意识的增强以及慢性病的增加正在推动对临床实验室服务的需求,预计临床实验室产业将在预测期内实现最高成长率。此外,诊断技术的进步以及对早期疾病检测和个人化医疗的关注正在推动对全面临床检测的需求。总的来说,这些因素正在推动临床检测产业的扩张,显示医疗保健产业的强劲成长潜力。
北美拥有先进的医疗基础设施并促进了对诊断和测试服务的高需求,因此能够主导市场。此外,随着製药和生物技术领域的强大,对专业实验室分析的需求也不断增加。此外,严格的监管标准需要全面的测试,进一步推动了对服务实验室的需求。主要产业参与者的存在、技术进步以及对研发的重视使得北美在服务实验室产业中占据了最大的市场占有率。
由于快速的工业化、技术进步以及医疗保健和製药等领域的研发活动的活性化,预计亚太地区的市场将显着成长。此外,严格的品质标准、快速成长的人口趋势以及产业外包趋势都推动了对实验室委託服务的需求。该地区不断发展的经济和对创新的重视使该地区成为服务实验室的重要中心,推动了市场的显着成长。
According to Stratistics MRC, the Global Service Laboratory Market is growing at a CAGR of 7.2% during the forecast period. Service Laboratory involves the use of specialised devices to monitor measure and detect ionising radiation levels in medical settings. These instruments ensure safety by tracking radiation exposure, assessing dosage during treatments like X-rays, CT scans or radiation therapy and safeguarding both patients and healthcare professionals from potential overexposure to radiation.
According to the Centers for Disease Control, 14 billion lab tests are conducted annually. It is estimated 70% of medical decisions are based on lab test results.
Increasing demand for diagnostic testing
With a growing focus on preventive healthcare and early disease detection, there's an increased need for accurate and advanced diagnostic tests. Factors like an aging population, escalating incidences of chronic diseases and technological advancements in diagnostic tools contribute to this demand surge. Consequently, service laboratories experience heightened requests for a diverse range of diagnostic tests, driving market growth as they cater to the escalating need for precise, timely and comprehensive diagnostic services across healthcare and related industries.
High operational and capital costs
The need for cutting-edge technology, specialised equipment, skilled personnel and stringent compliance with regulatory standards leads to substantial operational expenses. Additionally, the initial investment in setting up and maintaining state-of-the-art laboratories adds to the capital costs. These high operational and capital expenses can pose challenges for smaller players entering the market, limiting their ability to compete and invest in innovation.
Rise in personalized medicine
Personalised medicine relies on precise diagnostic tests and tailored treatments based on an individual's genetic makeup, lifestyle and specific health characteristics. This trend fuels the demand for advanced testing services, including genetic testing, biomarker analysis and molecular diagnostics, requiring specialised laboratories. Service laboratories catering to personalised medicine can offer comprehensive testing services, supporting healthcare providers in delivering more effective, targeted treatments, thereby driving the growth of personalised medicine and expanding opportunities within the service laboratory market.
Continuous technological advancements
Rapid technological evolution might render existing equipment or methodologies obsolete, necessitating frequent upgrades or investments in new technology. This constant need for adaptation and innovation places financial pressure on laboratories to stay competitive. Moreover, the rapid pace of change could create a gap between updated and legacy systems, impacting standardisation and consistency in testing procedures and potentially challenging service providers to maintain a balance between adopting new technologies and ensuring continuity and reliability in their services.
The COVID-19 pandemic significantly affected the service laboratory market, triggering increased demand for diagnostic testing services. Laboratories worldwide faced a surge in testing requirements for virus detection, leading to operational challenges, supply chain disruptions and workforce constraints. Additionally, the pandemic accelerated research and development activities, emphasising the importance of service laboratories in disease diagnosis, treatment development and public health response strategies.
The routine testing segment is expected to be the largest during the forecast period
The routine testing segment is anticipated to be the largest during the forecast period, primarily owing to its widespread application across various industries and everyday processes. Industries such as pharmaceuticals, food and beverage and manufacturing heavily rely on routine testing for quality assurance and regulatory compliance. As a result, the consistent demand for regular, standardised testing procedures positions the routine testing segment as the dominant and largest contributor to the broader testing services market during the forecast period.
The clinical testing segment is expected to have the highest CAGR during the forecast period
The clinical testing segment is projected to achieve the highest growth rate during the forecast period owing to increasing healthcare expenditure, growing awareness about preventive healthcare and a rise in chronic diseases, which drive the demand for clinical testing services. Moreover, advancements in diagnostic technologies, coupled with a focus on early disease detection and personalised medicine, propel the need for comprehensive clinical testing. These factors collectively fuel the expansion of the clinical testing segment, indicating robust growth potential in the healthcare industry.
North America is positioned to dominate the market due to the region's advanced healthcare infrastructure, which fosters a high demand for diagnostic and testing services. Additionally, a robust pharmaceutical and biotechnology sector drives the need for specialised laboratory analyses. Moreover, stringent regulatory standards necessitate comprehensive testing, further boosting the demand for service laboratories. The presence of major industry players, technological advancements and a strong emphasis on research and development collectively contribute to North America's largest market share in the service laboratory industry.
The Asia-Pacific region anticipates significant growth in the market due to rapid industrialization, technological advancements and increasing research and development activities across sectors like healthcare and pharmaceuticals. Additionally, stringent quality standards, a burgeoning population and the outsourcing trend in industries fuel the need for outsourced laboratory services. This region's expanding economies and the emphasis on innovation position it as a key hub for service laboratories, fostering substantial market growth.
Key players in the market
Some of the key players in Service Laboratory Market include Abbott Laboratories, ACM Global Laboratories, Agilent Technologies, Beckman Coulter, BioReference Laboratories, Bruker Corporation, Charles River Laboratories, Eurofins Scientific, Genomic Health, Labcorp, NeoGenomics Laboratories, PerkinElmer, Qiagen NV, Quest Diagnostics, Roche Diagnostics, Siemens Healthineers, Sonic Healthcare, SYNLAB International GmbH, Thermo Fisher Scientific and Waters Corporation.
In June 2023, IMCD inaugurated an additional facility close to Philadelphia. To better serve its clients in North America, IMCD announced the relocation and opening of its "IMCD Coatings & Construction Laboratory.
In June 2022, Labcorp, a paramount global life sciences company, announced the expansion of CB Trial Laboratory, the central laboratory shared by Labcorp Drug Development and BML, a top Japanese provider of clinical laboratory testing services, to strengthen its central laboratory presence and drug development capabilities in Japan.